Industry NewsLife Sciences
ERS Genomics and StemSight sign CRISPR/Cas9 license agreement
License agreement provides StemSight access to CRISPR/Cas9 technology to be applied in the development of cell therapies for corneal blindness
View articleNews & Articles
25
Best match